gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Abstract

In patients with advanced melanoma, the response rate was higher and progression-free survival longer with vaccine and interleukin-2 than with interleukin-2 alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00019682.).